AF-termination Biomarkers pilot study

  • Research type

    Research Study

  • Full title

    A pilot study: Sequential sampling of Blood and MRI based biomarkers of thrombogenesis following termination of Atrial Fibrillation episodes.

  • IRAS ID

    370235

  • Contact name

    Tim R Betts

  • Contact email

    tim.betts@ouh.nhs.uk

  • Sponsor organisation

    Oxford University Hospitals NHS Foundation Trust

  • Duration of Study in the UK

    1 years, 0 months, 0 days

  • Research summary

    This study will recruit 12 patients with Atrial Fibrillation (AF), the most common sustained heart-rhythm disturbance. AF is associated with increased risk of clot-formation in the heart, leading to ischaemic stroke.

    The study aims to test biological markers (biomarkers) relating to clot-formation risk, both before and after episodes of AF. We aim to use this pilot data from a small group of patients to guide development of a larger study. This larger study will aim to answer the question: "for how long after an AF episode does the clot-formation risk remain elevated?"

    This question is particularly relevant to an emerging treatment approach known as intermittent anticoagulation. In this approach, AF patients only take their blood-thinner in response to AF episodes. How long they should continue the blood-thinner after the episode is not currently known. This is the knowledge gap we are aiming to fill.

    In this current pilot study, patients will undergo 2 or 3 biomarker sampling visits when they will have blood samples taken and undergo an MRI-scan of their heart. In patients with short episodes of AF, there will be two biomarker visits: one before any AF has occurred, and one 7-days after AF. In patients with sustained AF (persistent), there will be three biomarker visits: one before their planned cardioversion procedure, then one at 7 days and another at 30 days following the procedure.

    Eligible AF patients must have either Paroxysmal AF and an implantable loop recorder, or Persistent AF and be awaiting a cardioversion. All visits will be at John Radcliffe Hospital, Oxford. Visits will take 1-2 hours each. The study follow-up period will be 11 months.

  • REC name

    South West - Cornwall & Plymouth Research Ethics Committee

  • REC reference

    26/SW/0079

  • Date of REC Opinion

    5 Aug 2026

  • REC opinion

    Further Information Favourable Opinion